1 · Quick ED Algorithm
Low Mg²⁺ → assess symptoms + ECG → check K⁺ / Ca²⁺ / renal function
↓
Mild + asymptomatic → oral Mg²⁺ + treat the cause
↓
Severe / symptomatic → IV Mg²⁺ + monitor
↓
Torsades / life-threatening arrhythmia → resuscitation + IV Mg²⁺ + correct K⁺ + remove causes
↓
Recheck Mg²⁺ / K⁺ / Ca²⁺ → treat the underlying cause
2 · Initial Assessment
- ABCDE approach
- Assess haemodynamic stability
- 12-lead ECG
- Cardiac monitoring when clinically indicated
- IV access for significant/symptomatic hypomagnesaemia
- Repeat magnesium if a laboratory error is suspected
- Check: magnesium, potassium, calcium, sodium, phosphate, renal function/eGFR, glucose, ECG, and acid–base status where clinically relevant
- Hypomagnesaemia commonly coexists with hypokalaemia and hypocalcaemia.
- Related EMOnCall protocols: Acute Hyperkalaemia — Adult · Acute Hypokalaemia — Adult
3 · Severity Classification
- Mild / asymptomatic: serum magnesium approximately 0.5–0.7 mmol/L (some sources use 0.4–0.7 mmol/L)
- Severe / symptomatic: serum magnesium approximately <0.5 mmol/L (some sources use <0.4 mmol/L)
- Normal reference range: approximately 0.7–1.0 mmol/L (check your local laboratory range)
- Treat these as approximate bands, not hard cut-offs — sources vary slightly in exactly where they draw the mild/severe boundary
- Distinguish a laboratory abnormality from clinically significant hypomagnesaemia — base treatment decisions on the whole picture: absolute magnesium level, symptoms, ECG abnormalities, arrhythmia, seizures, associated electrolyte abnormalities, renal function, and the rate of decline
4 · Clinical Features
- Neuromuscular: weakness, tremor, muscle cramps, fasciculations, tetany, hyperreflexia, seizures, altered mental status
- Cardiac: palpitations, prolonged QT, ventricular ectopy, atrial/ventricular arrhythmias, torsades de pointes
- Associated electrolyte abnormalities: hypokalaemia, hypocalcaemia, and hypokalaemia that is refractory to potassium replacement alone
- Consider hypomagnesaemia in unexplained or refractory hypokalaemia.
5 · ECG
- QT prolongation
- Ventricular ectopy
- Torsades de pointes
- Other potentially serious arrhythmias
- A normal ECG does NOT exclude clinically significant hypomagnesaemia.
6 · When to Replace Magnesium — Oral vs IV
- Oral replacement is appropriate for mild, asymptomatic hypomagnesaemia in a patient who can safely take oral medication
- IV replacement is indicated for: severe hypomagnesaemia; symptomatic patients; seizures; significant arrhythmia; torsades de pointes; inability to tolerate oral treatment; significant ongoing losses; or associated severe electrolyte abnormalities where IV replacement is clinically appropriate
- The exact threshold for choosing IV over oral is a clinical judgement based on severity, symptoms and context — not a single fixed number
7 · Oral Magnesium
- Commonly used preparations: magnesium aspartate sachets (~10 mmol elemental magnesium per sachet); magnesium citrate tablets (~4 mmol); magnesium glycerophosphate preparations (~1.6–5 mmol per dose)
- Dose — refers to mmol of elemental magnesium, not the salt weight: a typical adult starting dose is 10 mmol once or twice daily (e.g. one magnesium aspartate sachet dissolved in 50–200 mL water, tea or juice), adjusted to response and local formulary
- Duration/monitoring: an initial course of around 3 days, then review the need for continued replacement based on repeat magnesium levels
- Adverse effects: diarrhoea is common and dose-limiting; GI tolerability often limits how much can be replaced orally
- Limitation: oral absorption is limited and slow — not suitable for severe or symptomatic hypomagnesaemia, or when rapid correction is needed
8 · IV Magnesium Replacement
- Severe but stable hypomagnesaemia (including oral-intolerant patients with milder deficiency): magnesium sulfate 8 mmol (4 mL of 50% solution) diluted in 100 mL 0.9% sodium chloride or 5% glucose, IV over 1 hour
- Severe / symptomatic hypomagnesaemia (excluding torsades/life-threatening arrhythmia — see section 9): magnesium sulfate 20 mmol (10 mL of 50% solution) diluted in at least 100 mL 0.9% sodium chloride or 5% glucose, IV over at least 3 hours, not exceeding 8 mmol/hour; further doses may be given based on repeat levels, up to a cumulative course of around 160 mmol over 5 days in ongoing severe deficiency
- Maximum peripheral concentration: approximately 5% magnesium sulfate solution (i.e. 20 mmol/100 mL) — the 50% concentrate must always be diluted before use
- Cardiac monitoring: recommended during IV magnesium in patients with significant symptoms (tetany, seizures, arrhythmia); monitor BP, heart rate and respiratory rate during any IV magnesium infusion
- Torsades de pointes / life-threatening ventricular arrhythmia is treated differently and faster — see the dedicated emergency section below, not the routine doses above
9 · Torsades de Pointes / Life-Threatening Ventricular Arrhythmia
- Immediate ABC assessment and continuous cardiac monitoring
- Defibrillation according to current ALS guidance if the rhythm is pulseless or haemodynamically unstable — do not delay defibrillation to give magnesium if the patient is peri-arrest/unstable
- IV magnesium (peri-arrest, pulse present): magnesium sulfate 2 g (8 mmol) IV over 10 minutes; may be repeated once after 5–15 minutes if the arrhythmia persists
- IV magnesium (pulseless cardiac arrest due to torsades): give as a rapid IV bolus (over 1–2 minutes) in line with standard ALS drug administration, then continue standard ALS
- Correct hypokalaemia simultaneously — hypokalaemia and hypomagnesaemia frequently coexist and both promote torsades
- Stop/review QT-prolonging medications immediately
- Treat reversible causes (electrolyte abnormalities, bradycardia, drug toxicity)
- Senior/critical care involvement early — this is a medical emergency
- This regimen is a specific exception to routine magnesium dosing above; it is faster and more concentrated because of the immediate arrhythmia risk
10 · Seizures / Neurological Symptoms
- Manage active seizures according to standard ALS/emergency seizure management principles
- Give IV magnesium replacement where hypomagnesaemia is thought to be contributing (see section 8)
- Correct associated electrolyte abnormalities (potassium, calcium) alongside magnesium
- Investigate and treat the underlying cause of the seizure — do not assume every seizure is caused by hypomagnesaemia; continue standard seizure work-up
11 · Associated Hypokalaemia
- Magnesium deficiency can cause renal potassium wasting
- Hypokalaemia may be refractory to potassium replacement until magnesium is corrected
- Check magnesium in any significant or unexplained hypokalaemia, and replace it when deficient
- Continue potassium monitoring and replacement according to the clinical situation alongside magnesium correction
- See the full EMOnCall Hypokalaemia protocol: Acute Hypokalaemia — Adult
12 · Associated Hypocalcaemia
- Hypomagnesaemia can contribute to hypocalcaemia, partly through impaired parathyroid hormone secretion and action
- Assess serum calcium in significant hypomagnesaemia
- Consider ionised calcium where clinically appropriate, particularly if albumin-corrected total calcium is difficult to interpret
- Correct significant calcium abnormalities according to the clinical context — magnesium correction alone may not fully resolve hypocalcaemia if calcium replacement is also needed
13 · Find and Treat the Cause
- Gastrointestinal: diarrhoea; vomiting; malabsorption; chronic proton-pump-inhibitor-associated deficiency; high-output GI losses (fistulae, stomas)
- Renal: diuretics; renal magnesium wasting; aminoglycosides; cisplatin; calcineurin inhibitors; other nephrotoxic medications
- Other: alcohol-related nutritional deficiency; malnutrition; refeeding syndrome; pancreatitis; uncontrolled diabetes/osmotic diuresis; critical illness
- Medication review: identify and reassess any medications contributing to magnesium loss
14 · Drug-Induced Hypomagnesaemia
- Proton-pump inhibitors
- Loop diuretics
- Thiazide diuretics
- Aminoglycosides
- Cisplatin
- Calcineurin inhibitors (e.g. tacrolimus, ciclosporin)
- Other recognised magnesium-wasting medications
- Review and modify contributing medications where clinically appropriate — weigh the indication for the drug against the severity of hypomagnesaemia
15 · Renal Impairment
- RENAL IMPAIRMENT → HIGHER RISK OF MAGNESIUM ACCUMULATION.
- Check renal function before IV replacement
- Severe renal impairment (eGFR <30 mL/min): reduce IV magnesium doses to approximately 50% or less of the standard dose
- Give single, smaller doses and reassess using repeat serum magnesium levels rather than committing to a full multi-day course upfront
- Monitor magnesium more closely for accumulation/toxicity
- Seek senior/renal advice for severe renal impairment or dialysis-dependent patients
16 · Monitoring
- Serum magnesium: recheck at least 12 hours after an IV infusion, ideally sampled from the arm opposite the infusion site
- Potassium and calcium: monitor daily alongside magnesium (U&E including Mg, K, Ca) during replacement
- Renal function: monitor throughout, particularly with repeated or higher-dose IV replacement
- ECG / cardiac rhythm: continuous monitoring during IV replacement in symptomatic patients or where arrhythmia/ECG changes are present
- Neurological symptoms: reassess tetany, tremor, hyperreflexia and mental status as treatment progresses
- Infusion-site monitoring throughout peripheral IV replacement
- Frequency should be individualised to severity, route, dose, infusion rate, renal function and symptoms/arrhythmia — increase monitoring frequency for any of these that are more severe
17 · Disposition
- Possible ED discharge: mild/asymptomatic; cause identified and addressed; safe oral replacement in place; no significant ECG abnormality; appropriate follow-up arranged
- Admission: severe hypomagnesaemia; symptomatic patients; seizures; significant arrhythmia; significant associated electrolyte abnormalities; ongoing losses; inability to tolerate oral replacement; significant renal or medical comorbidity
- ICU/HDU / urgent senior review: torsades; unstable arrhythmia; seizures; haemodynamic instability; severe electrolyte abnormalities; need for intensive IV replacement/monitoring
18 · Red Flags — Urgent Senior / Critical Care Review
- Torsades de pointes
- Ventricular arrhythmia
- Significant QT prolongation
- Seizures
- Severe symptomatic hypomagnesaemia
- Severe hypokalaemia associated with magnesium deficiency
- Severe hypocalcaemia
- Significant renal impairment
- Recurrent/refractory hypomagnesaemia
19 · Safety Warnings
- CHECK RENAL FUNCTION BEFORE IV MAGNESIUM.
- DO NOT GIVE IV MAGNESIUM AS A RAPID IV PUSH UNLESS SPECIFICALLY INDICATED BY THE EMERGENCY/RESUSCITATION PROTOCOL (i.e. torsades/pulseless arrest — section 9)
- USE THE CORRECT PREPARATION AND CONCENTRATION.
- MONITOR FOR MAGNESIUM TOXICITY IN RENAL IMPAIRMENT.
- CHECK AND CORRECT ASSOCIATED HYPOKALAEMIA.
- CHECK CALCIUM.